Phytoestrogens: Next generation ERα modulators in osteoporosis treatment – in silico approach and ADMET evaluation

Sukru Akmese; Ibrahim Bektas; Bisar Amac; Omer Goc

doi:10.5281/ zenodo.18527400

Authors

Sukru Akmese Department of Medicinal Biochemistry, Medical Faculty, Harran University, Sanlıurfa, Turkey https://orcid.org/0000-0003-4992-0281
Ibrahim Bektas Department of Pharmacy Services, Health Services Vocational School, Harran University, Sanliurfa, Turkey https://orcid.org/0000-0001-9430-9735
Bisar Amac Department of Perfusion, Faculty of Health Sciences, Harran University, Sanliurfa, Turkey https://orcid.org/0000-0003-0320-4239
Omer Goc Department of Perfusion, Faculty of Health Sciences, Harran University, Sanliurfa, Turkey https://orcid.org/0000-0002-3047-6232

DOI:

https://doi.org/10.5281/%20zenodo.18527400

Keywords:

Osteoporosis, Estrogen Receptor Alpha, Molecular Docking, ADMET, Polyphenols

Abstract

Objective: Osteoporosis is a common metabolic bone disease caused by an imbalance between bone formation and resorption. Estrogen deficiency plays a critical role, especially in postmenopausal osteoporosis. The side effects of current treatments (bisphosphonates, SERMs) necessitate the investigation of safe phytoestrogen-based alternatives that exert a bone-protective effect via the estrogen receptor alpha (ERα). The aim of this study is to investigate the potential agonistic effects of nine different phytoestrogens on ERα using in silico methods.

Materials and methods: In this study, molecular docking simulations were performed with phytoestrogens and the reference modulator tamoxifen using the ERα crystal structure (PDB: 3ERT). Binding affinities (kcal/mol) and ligand-protein interactions were determined with these simulations. In addition, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) analyses were performed to evaluate drug similarity and safety profiles.

Results: In docking analyses, coumestrol and genistein (-8.9 kcal/mol) stood out as the compounds with the highest binding affinity and achieved better scores than tamoxifen (-8.7 kcal/mol). These high-affinity compounds exhibited an agonistic binding mode similar to the native agonist and tamoxifen by forming hydrogen bonds with Glu353 and Arg394, key residues in the ERα ligand binding site. ADMET analyses showed that all phytoestrogens studied conformed to Lipinski rules and had generally acceptable pharmacokinetic and toxicity profiles.

Conclusion: The obtained in silico data support the idea that phytoestrogens, particularly coumestrol, genistein, and daidzein, have the potential for tamoxifen-like agonistic activity by targeting ERα and could be developed as new and safer therapeutic agents in the treatment of osteoporosis.

References

Cheng C-H, Chen L-R, Chen K-H. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. 2022;23(3):1376.

Zhang W, Gao R, Rong X, Zhu S, Cui Y, Liu H, et al. Immunoporosis: role of immune system in the pathophysiology of different types of osteoporosis. Front Endocrinol (Lausanne). 2022;13:965258.

Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary osteoporosis. Endocr Rev. 2022;43(2):240-313.

Zhu H, Jiang J, Wang Q, Zong J, Zhang L, Ma T, et al. Associations between ERα/β gene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMC Endocr Disord. 2018;18(1):11.

Liang B, Burley G, Lin S, Shi YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett. 2022;27(1):72.

Krum SA, Brown M. Unraveling estrogen action in osteoporosis. Cell Cycle. 2008;7(10):1348-52.

Morin SN, Leslie WD, Schousboe JT. Osteoporosis: a review. JAMA. 2025;334(10):894-907.

Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, et al. Theoretical investigation of the role of the RANK–RANKL–OPG system in bone remodeling. J Theor Biol. 2010;262(2):306-16.

Chi G, Qiu L, Ma J, Wu W, Zhang Y. The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis. J Orthop Surg Res. 2023;18(1):839.

Zhang H, Recker R, Lee W-NP, Xiao GG. Proteomics in bone research. Expert Rev Proteomics. 2010;7(1):103-11.

Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121-32.

Gao Y, Chen N, Fu Z, Zhang Q. Progress of Wnt signaling pathway in osteoporosis. Biomolecules. 2023;13(3):483.

Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31(3):266-300.

Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007;282(37):27298-305.

Khalid AB, Krum SA. Estrogen receptors alpha and beta in bone. Bone. 2016;87:130-5.

Imai Y, Kondoh S, Kouzmenko A, Kato S. Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha. Mol Endocrinol. 2010;24(5):877-85.

Palacios S. Medical treatment of osteoporosis. Climacteric. 2022;25(1):43-9.

Seo H, Seo H, Lee S-H, Park Y. Receptor mediated biological activities of phytoestrogens. Int J Biol Macromol. 2024;278:134320.

Pachiappan S, Muthusamy G, Sivakumar A. Exploring The Effect of Phytoestrogens on Bone Density and Osteoporosis Prevention. Int J of Pharm Sci. 2025;3(7):1719-35.

Nadia ME, Nazrun AS, Norazlina M, Isa NM, Norliza M, Ima Nirwana S. The anti-inflammatory, phytoestrogenic, and antioxidative role of Labisia pumila in prevention of postmenopausal osteoporosis. Adv Pharmacol Pharm Sci. 2012;2012:706905.

Liu J, Deng X, Liang X, Li L. The phytoestrogen glabrene prevents osteoporosis in ovariectomized rats through upregulation of the canonical Wnt/β-catenin signaling pathway. J Biochem Mol Toxicol. 2021;35(2):e22653.

Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331.

Gül Dikme T, Necip A, Dikme R, Güneş S. Effect of phytosterols in apricot kernel on cholesterol—molecular docking. Mehes J. 2024;2(3):28-37.

Dong J, Wang N-N, Yao Z-J, Zhang L, Cheng Y, Ouyang D, et al. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform. 2018;10(1):29.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.

Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699-712.

Melville KM, Kelly NH, Khan SA, Schimenti JC, Ross FP, Main RP, et al. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J Bone Miner Res. 2013;29(2):370-9.

Gomes B, Vale N. Impact of endocrine therapy on osteoporosis risk in women with breast cancer across different hormonal stages: a review. Curr Oncol. 2025;32(6):305.

Perry MJ, Gujra S, Whitworth T, Tobias JH. Tamoxifen stimulates cancellous bone formation in long bones of female mice. Endocrinology. 2005;146(3):1060-5.

Bafna D, Ban F, Rennie PS, Singh K, Cherkasov A. Computer-aided ligand discovery for estrogen receptor alpha. Int J Mol Sci. 2020;21(12):4193.

de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011;2011:232435.

Puranik NV, Srivastava P, Bhatt G, John Mary DJS, Limaye AM, Sivaraman J. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach. Sci Rep. 2019;9(1):7450.